clevidipine

Contraindicated in:

Hypersensitivity;
Allergy to soybeans or eggs/egg products;
Defective lipid metabolism including pathologic hyperlipidemia, lipoid nephrosis or acute pancreatitis;
Severe aortic stenosis.

Use Cautiously in:

OB: Safety not established in pregnancy;
Lactation: Safety not established in breastfeeding;
Pedi: Safety and effectiveness not established in children;
Geri: Initiate therapy at low end of dose range and titrate dose cautiously in older adults.

Adv. Reactions/Side Effects ⬆ ⬇

CV: HF, hypotension, rebound hypertension, reflex tachycardia

GI: nausea, vomiting

MS: arthralgia

Neuro: headache

Resp: hypoxemia

Interactions ⬆ ⬇

Drug-drug:

↑risk of excess hypotension with other antihypertensives.
Does not protect against effects of abrupt beta blocker withdrawal.

Availability ⬆ ⬇

Emulsion for injection: 0.5 mg/mL

Route/Dosage ⬆ ⬇

IV (Adults ): 1–2 mg/hr initially, then double dose every 90 sec initially; as BP approaches goal, ↑ dose by less than doubling and lengthen the time between dose adjustments to every 5–10 min. Usual dose required is 4–6 mg/hr. Doses up to 32 mg/hr have been used, but generally should not exceed 21 mg/hr in a 24 hr period due to lipid load.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Inhibits calcium transport into vascular smooth muscle, resulting in inhibition of excitation-contraction coupling and subsequent contraction.
Decreases systemic vascular resistance; does not reduce cardiac filling pressure (preload). Has no effect on venous capacitance vessels.

Therapeutic effects:

Decreases BP.

Classifications ⬆ ⬇

Therapeutic Classification: antihypertensives

Pharmacologic Classification: calcium channel blockers (dihydropyridine)

Pharmacokinetics ⬆ ⬇

Absorption: IV administration results in complete bioavailability.

Distribution: Minimally distributed to tissues.

Protein Binding: >99.5%.

Metabolism/Excretion: Rapidly metabolized by esterases in plasma and tissue to inactive metabolites; metabolites are excreted in urine (63–74%) and feces (7–22%).

Half-Life: Initial phase: 1 min; terminal phase: 15 min.

Time/Action Profile ⬆ ⬇

ROUTE	ONSET	PEAK	DURATION
IV	2–4 min	30 min*	end of infusion

*Time to target BP.

Patient/Family Teaching ⬆ ⬇

Explain purpose and side effects of medication. Advise patient to read Patient Information before starting therapy, as able before infusion.
Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult health care professional before taking other medications.
Encourage patients with underlying hypertension to continue follow-up care and to continue taking their oral antihypertensive medication(s) as directed.
Rep: Advise women of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Pronunciation ⬆ ⬇

Code ⬆

NDC Code

18124- Fresenius Kabi Austria GmbH
- 18124-011- Cleviprex
  - 18124-011-00- 10 CARTON in 1 CARTON (18124-011-00) / 1 VIAL, SINGLE-USE in 1 CARTON / 100 mL in 1 VIAL, SINGLE-USE

18124- Fresenius Kabi Austria GmbH
- 18124-011- Cleviprex
  - 18124-011-25- 4 CARTON in 1 CARTON (18124-011-25) / 1 VIAL, SINGLE-USE in 1 CARTON / 250 mL in 1 VIAL, SINGLE-USE

18124- Fresenius Kabi Austria GmbH
- 18124-011- Cleviprex
  - 18124-011-50- 10 CARTON in 1 CARTON (18124-011-50) / 1 VIAL, SINGLE-USE in 1 CARTON / 50 mL in 1 VIAL, SINGLE-USE

33656- Chongqing Biocare Pharmaceutical Ltd.
- 33656-0013-
  - 33656-0013-1- 1 kg in 1 DRUM (33656-0013-1)

50137- Veranova, L.P.
- 50137-2930-
  - 50137-2930-1- 1 kg in 1 CONTAINER (50137-2930-1)

63673- Zhongfu Pharmaceutical Co., Ltd.
- 63673-0001-
  - 63673-0001-1- 100 g in 1 BAG (63673-0001-1)

section name header

Indications ⬇

Contraind./Precautions ⬆ ⬇